Skip to main content

Table 1 Comparisons of demographic and clinical characteristics of patients in the three antipsychotic groups

From: High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey

  Olanzapine
(N = 356)
Risperidone
(N = 529)
Aripiprazole
(N = 222)
p-value
Age years 56.4 ± 14.0 60.2 ± 13.2 54.8 ± 15.2 < 0.001
Females (males)   158 (198) 243 (286) 115 (107) 0.201
Outpatients (inpatients)   138 (218) 194 (335) 101 (121) 0.077
BMI kg/m2 23.2 ± 4.1 23.5 ± 4.5 23.5 ± 5.1 0.516
Waist circumference cm 84.0 ± 11.5 84.8 ± 11.7 83.4 ± 14.1 0.297
Systolic blood pressure mmHg 124.5 ± 18.9 122.7 ± 17.3 123.9 ± 19.1 0.355
Diastolic blood pressure mmHg 77.2 ± 12.3 75.0 ± 12.5 74.9 ± 13.0 0.025
HDL-cholesterol mg/dL 54.3 ± 18.6 55.4 ± 17.9 57.5 ± 17.9 0.126
CP-equivalent dosage of current AAP mg 516.1 ± 261.7 420.8 ± 273.4 402.1 ± 231.7 < 0.001
Concomitant drugs
 Antidepressant   1 0 0  
 Mood stabilizer   6 11 3  
 Benzodiazepines   7 13 2  
 Anticholinergic drug   0 9 0  
  1. Data are shown as the mean ± SD or number of subjects
  2. Age, BMI, waist circumference, systolic blood pressure, diastolic blood pressure, HDL-cholesterol, and CP-equivalent dosage of current AAP were compared among the three antipsychotics groups. The chi-square test was performed to analyze sex and outpatients (inpatients)
  3. BMI body mass index, HDL high-density lipoprotein, CP chlorpromazine, AAP atypical antipsychotic